Precipio, Inc. (PRPO)

USD 5.56

(-3.81%)

Market Cap (In USD)

8.24 Million

Revenue (In USD)

15.19 Million

Net Income (In USD)

-5.85 Million

Avg. Volume

10.28 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
4.31-7.3
PE
-
EPS
-
Beta Value
1.424
ISIN
US74019L6020
CUSIP
74019L503
CIK
1043961
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Mr. Ilan Danieli
Employee Count
-
Website
https://www.precipiodx.com
Ipo Date
2017-06-30
Details
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.